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Abstract: Previously, macrophage inflammatory
protein-1a (MIP-1a), a member of the C-C chemo-
kine family, has been implicated in bleomycin-
induced pulmonary fibrosis, a model of the human
disease idiopathic pulmonary fibrosis. Neutraliza-
tion of MIP-1a protein with anti-MIP-1a antibodies
significantly attenuated both mononuclear phago-
cyte recruitment and pulmonary fibrosis in bleomy-
cin-challenged CBA/J mice. However, the specific
stimuli for MIP-1a expression in the bleomycin-
induced lesion have not been characterized. In this
report, two mediators of the inflammatory re-
sponse to bleomycin, tumor necrosis factor (TNF)
and interleukin-6 (IL-6), were evaluated as putative
stimuli for MIP-1a expression after bleomycin
challenge in CBA/J mice. Elevated levels of bioac-
tive TNF and IL-6 were detected in bronchoalveo-
lar lavage (BAL) fluid and lung homogenates from
bleomycin-treated CBA/J mice at time points post-
bleomycin challenge, which precede MIP-1a pro-
tein expression. Treatment of bleomycin-chal-
lenged mice with soluble TNF receptor (sTNFr) or
anti-IL-6 antibodies significantly decreased MIP-1a
protein expression in the lungs. Furthermore, nor-
mal alveolar macrophages secreted elevated levels
of MIP-1a protein in response to treatment with
TNF plus IL-6 or bleomycin plus IL-6, but not TNF,
bleomycin, or IL-6 alone. Finally, leukocytes recov-
ered from the BAL fluid of bleomycin-challenged
mice secreted higher levels of MIP-1a protein,
compared to controls, when treated with TNF
alone. Based on the data presented here, we pro-
pose that TNF and IL-6 are part of a cytokine
network that modulates MIP-1a protein expression
in the profibrotic inflammatory lesion during the
response to intratracheal bleomycin challenge.
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INTRODUCTION
Intratracheal instillation of bleomycin in CBA/J mice results in
a characteristic inflammatory lesion that culminates in pulmo-
nary fibrosis [1–6]. Factors that mediate this response to
bleomycin challenge include many types of inflammatory cells,
stromal cells, cytokines, and growth factors [7]. One member of
the C-C chemokine family, macrophage inflammatory pro-
tein-1a (MIP-1a), mediates mononuclear phagocyte recruit-
ment during the response to bleomycin [8]. In addition,
neutralization of MIP-1a protein with anti-MIP-1a antibodies
significantly attenuates the pulmonary fibrotic response in
CBA/J mice [8]. Although these data establish a central role for
MIP-1a in the bleomycin model, the specific stimuli for
MIP-1a protein expression have not been identified.
One likely stimulus for MIP-1a protein expression is tumor
necrosis factor (TNF). Neutralization of TNF after bleomycin
challenge also results in a dramatic decrease in inflammatory
cell accumulation and the subsequent pulmonary fibrosis [9,
10]. It is interesting to note that transient expression of TNF
protein and mRNA has been detected in whole lung and
bronchoalveolar lavage (BAL) preparations 3–8 days post-
bleomycin challenge, whereas MIP-1a protein expression
peaks at 2 and 12 days post-challenge [8, 9, 11]. Although the
expression of TNF protein before the early 2-day peak of
MIP-1a protein expression has not been characterized, the
temporal association of TNF and MIP-1a expression in the
bleomycin model leads us to hypothesize that TNF may be a
direct stimulus for the early (2 day) and late (12 day) peaks of
MIP-1a protein expression after bleomycin challenge.
Another candidate stimulus for MIP-1a expression is inter-
leukin-6 (IL-6). IL-6 is secreted by bleomycin-challenged rat
aortic endothelial cell or murine peritoneal macrophage cul-
tures but, in contrast to TNF and MIP-1a, the specific
contribution of IL-6 to the profibrotic lesion has not been
demonstrated [12, 13]. However, IL-6 serves as an important
cofactor for neutrophil activation and B cell stimulation,
suggesting that the contribution of IL-6 may be overlooked
when singly evaluated [14, 15]. Therefore, we evaluated IL-6 as
a factor that may synergize with other inflammatory mediators,
such as TNF, to stimulate MIP-1a expression after bleomycin
challenge.
In this study, we investigated TNF and IL-6 as putative
stimuli of MIP-1a protein expression in bleomycin-induced
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lung injury. Elevated levels of bioactive TNF and IL-6 were
detected in BAL fluid and lung homogenates from bleomycin-
treated CBA/J mice at time points post-bleomycin challenge,
which preceded MIP-1a protein expression. Treatment of
bleomycin-challenged mice with soluble TNF receptor (sTNFr)
or anti-IL-6 antibodies significantly decreased MIP-1a protein
expression in the lungs. By in situ hybridization, we identified
alveolar macrophages as a source of MIP-1a mRNA and as a
target for in vitro studies. Furthermore, normal alveolar macro-
phages secreted elevated levels of MIP-1a protein in response
to treatment with TNF plus IL-6 or bleomycin plus IL-6, but not
TNF, bleomycin, or IL-6 alone. Finally, leukocytes recovered
from the BAL fluid of bleomycin-challenged mice secreted
higher levels of MIP-1a protein than normal alveolar macro-
phages, both constitutively and when treated with TNF alone.
These findings suggest that TNF, IL-6, and bleomycin are
stimuli for MIP-1a expression and establish that these media-
tors are participants in a cytokine network present in the




Recombinant murine MIP-1a, murine TNF, and murine IL-6 were purchased
from R & D Systems, Minneapolis, MN. Serial dilutions of pyrogen-free
cytokines were prepared in sterile RPMI 1640 (Whitaker Biomedical Products,
Whitaker, CA), 1 mM glutamine, 25 mM HEPES, 100 units/mL penicillin, 100
ng/mL streptomycin (Hazelton Research Products, Denver, PA) (complete
media). CBA/J mice were purchased from Jackson Laboratories, Bar Harbor,
ME. Female New Zealand White rabbits were purchased from Hazelton
Research Products, Kalamazoo, MI. Blenoxane (bleomycin sulfate) was pur-
chased from Bristol-Myers Squibb Co., Evansville, IN. Ketalar (ketamine HCl)
was purchased from Parke-Davis, Morris Plains, NJ.
Bleomycin administration
Bleomycin was administered to CBA/J mice as previously described [8]. Briefly,
CBA/J mice were anesthetized with 250 µL of 12.5 µg/mL of ketamine injected
intraperitoneally, followed by intratracheal instillation of 0.025 units of
bleomycin (in 25 µL of sterile saline) or 25 µL of sterile isotonic saline. At 2 and
10 days post-instillation, animals were killed, cold sterile saline was perfused
into the right ventricle of the heart to remove blood from the lung vascular beds,
and both lungs removed for homogenization with a hand held tissue tearor
(Whatman, Hillsboro, OR). Whole lung homogenates were spun at 30,000 g for
35 min and supernatants removed for enzyme-linked immunosorbent assay
(ELISA) analysis. In separate experiments, at various times post-bleomycin
instillation, mice were killed and the lungs lavaged with 1.5–2.0 mL sterile
saline. BAL fluid (BALF) was centrifuged at 900 g for 10 min and the
supernatant frozen for ELISA or bioassay analysis. Pellets were resuspended in
0.5 mL normal saline, counted on a hemacytometer, and cytospun for
differential analysis. Alternatively, lungs were lavaged with 10 mL sterile
saline, the lavage fluid centrifuged at 900 g for 10 min, and the lavage cells
cultured in 96-well plates at 200,000 cells/well. BAL cell culture experiments
are a compilations of samples gathered on four separate occasions with different
litter groups of age matched CBA/J mice.
MIP-1a-specific ELISA
Antigenic murine MIP-1a was quantitated using a modification of the double
ligand method [16]. Briefly, flat-bottomed 96-well microtiter plates (Nunc
Immuno-Plate I 96-F) were coated with 50 µL/well of rabbit anti-murine
MIP-1a antibody (1 ng/µL in 0.6 M NaCl, 0.26 M H3BO4, and 0.08 N NaOH,
pH 9.6) for 16 h at 4°C and then washed with phosphate-buffered saline (PBS),
pH 7.5, 0.05% Tween-20 (wash buffer). Microtiter plate nonspecific binding
sites were blocked with 2% bovine serum albumin (BSA) in PBS and incubated
for 90 min at 37°C. Plates were rinsed four times with wash buffer and 50
µL/well of whole-lung homogenate or BALF was added and incubated for 1 h at
37°C. Plates were washed four times with wash buffer, then 50 µL/well of
biotinylated rabbit anti-MIP-1a (3.5 ng/µL in PBS, pH 7.5, 0.05% Tween-20,
and 2% fetal calf serum) was added, and plates incubated for 30 min at 37°C.
Plates were washed four times, streptavidin-peroxidase conjugate (Bio-Rad
Laboratories, Richmond, CA) was added, and the plates incubated for 30 min at
37°C. Plates were washed four times and chromogen substrate (Bio-Rad
Laboratories, Richmond, CA) was added. The plates were incubated at room
temperature to the desired extinction, and the reaction terminated with 50
µL/well of 3 M H2SO4. Plates were read at 490 nm in an ELISA reader.
Standards were 1/2 log dilutions of recombinant murine MIP-1a, from 1 pg/mL
to 100 ng/mL (50 µL/well). This ELISA method consistently detected MIP-1a
concentrations in a linear fashion greater than 50 pg/mL.
TNF and IL-6 bioassay
IL-6 levels were assayed from whole-lung homogenates with the use of a
sensitive and specific proliferation assay involving the IL-6-dependent murine
hybridoma cell line B13.29, Clone 9 (B9). Serial dilutions of samples were
incubated with 100 µL of B9 cells in 96-well plates at a concentration of 5 3
104 cells/mL for 72 h in a humidified incubator at 37°C with 5% CO2.
Proliferation was measured in a colorimetric assay using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) purchased from Sigma. During
the final 6 h of the incubation, 20 µL of MTT (5 mg/mL in PBS) were added to
each sample. The supernatant was aspirated from each well and 100 µL of
acidified isopropanol was added. Absorbance was measured at 550 nm. IL-6
concentrations in experimental samples were calculated using a standard curve
generated by serial dilutions of human rIL-6. This bioassay consistently
detected IL-6 concentrations .0.10 pg/mL.
TNF levels were assayed from whole lung homogenates with the use of a cell
death assay utilizing the TNF-sensitive WEHI 164 subclone 13 cell line. Serial
dilutions of test samples were incubated with 100 µL of WEHI cells at a
concentration of 5 3 105 cells/mL and 0.5 µg/mL actinomycin D for 24 h in a
humidified incubator at 37°C with 5% CO2. After an additional 6-h incubation
with 20 µL of MTT/well (5 mg/mL in PBS) the supernatant was aspirated from
each well, and 100 µL of acidified isopropanol was added, and the plates
isolated from light for 24 h. Absorbance was measured at 550 nm. TNF
concentrations in experimental samples were calculated using a standard curve
generated by serial dilutions of human rTNF. This bioassay consistently
detected TNF concentrations .0.10 pg/mL.
In situ hybridization
Three-micrometer paraffin-embedded serial lung sections from bleomycin-
challenged mice were deparaffinized by sequential treatment with xylene (15
min), 100% ETOH, 95% ETOH, 23 SSC, 0.2 N HCl (20 min), 23 SSC, 0.25%
acetic anhydride in triethanolamine (10 min), 23 SSC (70°C, 30 min), and 23
SSC. All treatments were 5 min unless otherwise noted. Slides were incubated
with pre-hybridization buffer [pre-hyb: 10% dextran sulfate (final), 33 SSC
(final), 23 Denhardts (final), 0.1 mg/mL salmon sperm DNA, 0.125 mg/mL
yeast tRNA, 0.01 mg/mL poly-A-poly-C, 1 mg/mL sodium pyrophosphate, and
50% deionized formamide (final), in DEPC H2O (to 100 mL)] for 2 h at 44°C.
About 15 µL pre-hyb solution was added to each tissue section. Some sections
were pretreated with 20 µL of 50 µg/mL solution of DNase-free RNase
(Boehringer Mannheim, Indianapolis IN). Anti-sense (5’-GAA-GCA-GCA-GGC-
AGT-CGG-GGT-GTC-AGC-TCC-3’) and sense probes for MIP-1a were end-
labeled with 35S-labeled ATP (DuPont-NEN, Wilmington, DE), purified by gel
electrophoresis, and assayed for specific activity. Pre-hyb was removed and 20
µL of hybridization buffer [hyb: pre-hyb plus 35S-labeled sense or anti-sense
probe (750,000 cpm/section) and 0.2 mg/mL dithiothreitol] were placed on
each tissue section. Slides were covered with an RNase-free coverslip and
incubated for 12–16 h at 44°C in a humidified chamber. Next, slides were
washed in 23 SSC for 2 h (changed six times), 13 SSC for 1 h, 0.53 SSC for
0.5 h, 0.53 SSC for 0.5 h at 44°C, 0.53 SSC for 0.5 h, 70% ETOH with 0.3 M
Smith et al. TNF mediates MIP-1a expression during lung injury 529
ammonium acetate for 2 min, and 100% ETOH with 0.3 M ammonium acetate
for 2 min. Slides were then air dried, dipped in NBT-2 emulsion (Kodak,
Rochester, NY), air dried again, and incubated for 18–21 days at 4°C in a
desiccated chamber. Slides were developed with D-19 developer, fixed with
Kodak rapid fix, counterstained with hematoxylin, and fixed with Permount
(Fisher Scientific, Fair Lawn, NJ).
Soluble TNF receptor (sTNFr) and anti-IL-6
antibody therapy
sTNFr was a generous gift from Immunex, Seattle, WA. One hour before
bleomycin challenge, CBA/J mice were given an intraperitoneal injection of
100 µg of sTNFr and/or 0.5 mL of anti-IL-6 immune serum and killed at 2 days
post challenge. In separate experiments, lungs from animals injected intraperi-
toneally with 100 µg sTNFr or 0.5 mL of anti-TNF immune serum 6 and 8 days
post-bleomycin administration were harvested 10 days post-challenge. CBA/J
mice treated as described above were analyzed for total lung MIP-1a protein
levels, BAL differential cell counts, and total cell counts. The in vivo half-life of
the sTNFr construct as previously reported is approximately 24 h [17]. To
determine dosage parameters and the in vivo half-life of anti-IL-6 immune
serum, mice injected intraperitoneally with anti-IL-6 serum or pre-immune
serum were bled at 6, 12, 24, and 48 h post-injection. Serum samples were
diluted 102–107 in sterile PBS and analyzed as described below. Ninety-six-
well plates (Nunc Immuno-Plate I 96-F) were coated with 50 µL of recombinant
murine IL-6 (1 µg/mL) and incubated at 4°C overnight. The plates were blocked
with 2% normal goat serum in PBS for 1 h at 37°C. Next, plates were washed
three times with wash buffer (PBS, pH 7.5, and 0.05% Tween-20). Fifty
microliters of diluted sample was added to each well and the plate incubated for
0.5 h at 37°C. The plates were again washed three times in wash buffer and 50
µL of peroxidase-labeled goat-anti-rabbit IgG diluted 1:400 in dilution buffer
(0.6 M NaCl, 0.26 M H3BO4, and 0.08 N NaOH, pH 9.6) was added to each well
and incubated for 0.5 h at 37°C. Plates were washed three times with wash
buffer, and 100 µL fresh chromogen substrate/well (Bio-Rad Laboratories) was
added. The plates were incubated at room temperature for 5 min. The reaction
was stopped with 50 µL/well of 3 M H2SO4. Plates were read at 490 nm in an
ELISA reader. A best fit curve was calculated and a plasma half-life of 60 h for
rabbit anti-IL-6 was calculated assuming linear clearance kinetics.
Statistical analysis
Data were evaluated by one-way analysis of variance and where appropriate,
further evaluated with either the parametric Student-Newman-Keuls test for
multiple comparisons or with the non-parametric Mann-Whitney rank sum test.
RESULTS
TNF protein is expressed immediately after
bleomycin challenge
Previous studies have characterized TNF mRNA and protein
expression in bleomycin-challenged CBA/J mice 4 and 7 days
post-challenge, which is before the late (12 day) peak of
MIP-1a protein expression reported in similarly treated mice
[8, 9, 11]. In addition, passive immunization with TNF antibod-
ies or soluble TNF receptor has been shown to abrogate the
fibrotic response to bleomycin [9, 18]. Consequently, we
hypothesized that TNF stimulates MIP-1a production in the
bleomycin model. To test this hypothesis we first completely
characterized the expression of TNF and another pro-
inflammatory cytokine, IL-6, in CBA/J mice at early time points
after bleomycin challenge. Elevated levels of bioactive TNF
and IL-6 protein were detected in BAL fluid from CBA/J mice
at 6, 12, and 24 h post-bleomycin challenge, compared to
controls (Fig. 1, A and B). In contrast, MIP-1a was not
increased in BAL fluid at 6 or 12 h, but was elevated at 24 h
post-bleomycin challenge (Fig. 1C). In separate experiments,
we characterized TNF and IL-6 expression at later time points.
Bioactive TNF was elevated in the BAL fluid of CBA/J mice 2,
8, and 16 days post-bleomycin challenge (Fig. 2B), whereas
bioactive IL-6 was elevated in whole lung homogenates of
bleomycin-challenged mice at all time points evaluated (Fig.
2A). The temporal sequences of TNF and IL-6 expression,
which precede both the early and late peaks of MIP-1a protein
expression, are compatible with the hypothesis that TNF and
IL-6 are stimuli for MIP-1a production in the bleomycin model.
Treatment with sTNFr attenuates inflammatory
cell accumulation and MIP-1a expression
To further investigate the hypothesis that TNF modulates
MIP-1a expression during the inflammatory response to bleomy-
cin, CBA/J mice were treated with a soluble TNF receptor
(sTNFr) construct that possesses potent neutralizing activity in
Fig. 1. Time course of TNF (A), IL-6 (B), and MIP-1a (C) ELISA (C) or
bioassay(A, B) analysis of BALF from bleomycin- or saline-challenged CBA/J
mice. Data expressed as mean 6 SEM, n 5 5, *P , 0.05.
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vivo [17]. Because MIP-1a protein and mRNA expression peak
at approximately 2 and 12 days post-challenge, we hypoth-
esized that sTNFr treatment would be most effective at the time
of bleomycin challenge (day 0) or before the second MIP-1a
peak (days 6 and 8) [8]. CBA/J mice treated with sTNFr, IgG, or
saline were challenged with 25 µL of 1 U/mL solution of
bleomycin or 25 µL of sterile saline. BAL and whole lung
homogenization were performed at 2 and 10 days post challenge
for quantitation of inflammatory cells or MIP-1a protein levels.
Lavage cells were quantitated and differential analysis was
performed to confirm the anti-inflammatory effects of the sTNFr
reagent. No significant differences in total cell counts (Fig. 3A)
or differential cell counts (data not shown) were detected 2 days
post-bleomycin challenge, consistent with previous findings
that total lavage cell populations are not elevated until 4 days
post-challenge [8]. However, at 10 days post-bleomycin chal-
lenge, sTNFr-treated mice had significantly reduced total
lavage cell populations compared to bleomycin and IgG-treated
controls (Fig. 3A). Differential analysis of lavage cells 10 days
post-challenge from sTNFr-treated mice detected reductions in
lymphocyte and mononuclear phagocyte but not granulocyte
populations compared to controls (Table 1). These results are
consistent with previous reports which demonstrate that neutral-
ization of TNF attenuates cellular accumulation in inflamma-
tory lesions [10, 19, 20]. After BAL, lungs from the above
animals were homogenized and analyzed for MIP-1a protein
levels. MIP-1a protein expression in CBA/J mice passively
immunized with sTNFr was significantly reduced at 2 days
post-bleomycin challenge, compared to IgG- and bleomycin-
treated controls, suggesting that TNF stimulates MIP-1a pro-
tein expression (Fig. 3B). In CBA/J mice treated with sTNFr 6
and 8 days post-bleomycin challenge, MIP-1a protein expres-
sion was not significantly decreased at day 10 (Fig. 3B).
However, in similar experiments, in CBA/J mice passively
immunized with anti-TNF polysera 6 and 8 days post-
bleomycin challenge, MIP-1a protein expression was signifi-
cantly decreased at day 10 (141 6 36 pg MIP-1a/animal)
compared to non-immune serum controls (549 6 78 pg
MIP-1a/animal, P , 0.05). These data strongly support the
hypothesis that TNF modulates both the early and late peaks of
MIP-1a protein expression in vivo.
Treatment with anti-IL-6 antibodies attenuates
MIP-1a expression
In experiments similar to the sTNFr studies above, CBA/J mice
were treated with IP injections of IgG, anti-IL-6 immune serum,
and/or sTNFr either before bleomycin administration or at 6
and 8 days post challenge. Lungs were homogenized and the
concentration of MIP-1a protein determined by ELISA analysis
at 2 and 10 days post challenge. MIP-1a protein expression in
CBA/J mice passively immunized with anti-IL-6 antibodies
alone was significantly reduced at 2 days post-bleomycin
challenge, compared to IgG- and bleomycin-treated controls
(Fig. 4). Combination of anti-IL-6 immune serum and sTNFr
therapy resulted in a larger decrease in MIP-1a expression at 2
days post challenge than that mediated by anti-IL-6 alone (Fig.
4). In CBA/J mice treated with anti-IL-6 immune serum 6 and 8
days post-bleomycin challenge, MIP-1a protein expression was
not significantly decreased at day 10 (data not shown). These
data suggest that IL-6 contributes to stimulation of the first
peak of MIP-1a protein expression at 2 days post challenge, but
not the second peak at 10 days.
In situ hybridization: localization of MIP-1a
mRNA 6 h post-bleomycin challenge
To determine whether TNF and IL-6 are directly or indirectly
stimulating MIP-1a expression, we moved to an in vitro model
where exogenous stimuli could be easily controlled. To confirm
that alveolar macrophages produce MIP-1a during the re-
sponse to bleomycin in vivo, we challenged CBA/J mice with 50
mU bleomycin sulfate, killed the animals 6 h post-challenge,
and removed the lungs for processing. In situ hybridization
using an anti-sense probe for MIP-1a mRNA specifically
labeled alveolar macrophages, identifying this cell type as a
potential source of MIP-1a protein (Fig. 5, A and B). Serial
sections probed with a sense MIP-1a probe (Fig. 5, C and D) or
pretreated with RNase (Fig. 5, inset E and inset F) were not
Fig. 2. Time course of IL-6 (A) and TNF
(B) bioassay analysis of BALF and whole
lung homogenates, respectively, from bleomy-
cin- or saline-challenged CBA/J mice. Data
expressed as mean 6 SEM, n 5 5, *P ,
0.05.
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specifically labeled. Animals challenged with saline had a
similar cellular labeling pattern, but with much less frequency
and intensity (data not shown). These results are consistent with
previous experiments demonstrating immunohistochemical
staining of MIP-1a protein in lung sections of CBA/J mice 1–2
days post-bleomycin challenge, and identify the alveolar macro-
phage as a potential source of MIP-1a protein expression in the
bleomycin-induced lesion [8].
Stimulus-specific MIP-1a secretion from alveolar
macrophages in vitro
To directly evaluate putative stimuli for MIP-1a expression,
normal alveolar macrophages isolated from CBA/J mice were
incubated with various factors known to be present in the
bleomycin-induced pulmonary lesion. Cells obtained via BAL
were $95% macrophages as determined by differential analy-
sis. We detected significantly elevated MIP-1a protein in the
supernatants of lavage cells incubated with 5 ng/mL IL-6 plus
either 5 mU/mL bleomycin sulfate or 5 ng/mL TNF, compared
to controls (Fig. 6A). MIP-1a levels in supernatants from cells
stimulated with similar concentrations of IL-6, bleomycin,
and/or TNF alone were not significantly different from controls
(Fig. 6A). These data suggest that TNF alone is not sufficient for
stimulation of MIP-1a secretion in resting alveolar macro-
phages and that IL-6 may be an important co-stimulatory
molecule in this system.
Although analysis of normal lavage cells is a reasonable
approximation of events early in the response to bleomycin,
evaluation of TNF and IL-6 as putative stimuli for the late
MIP-1a peak required a different approach. Here we chal-
lenged CBA/J mice with bleomycin and isolated BAL cells 8
days post-challenge. Previously, we demonstrated that the
8-day BAL cell population contained 64% macrophages, 21%
polymorphonuclear neutrophils, and 15% lymphocytes by
differential analysis [8]. Cells were stimulated with combina-
tions of IL-6, bleomycin, and/or TNF for 24 h and the
supernatants analyzed for MIP-1a protein. BAL cells from
bleomycin-challenged animals constitutively secreted an order
of magnitude more MIP-1a protein per 2 3 105 cells than BAL
cells from unchallenged animals (Figs. 6, A and B). In addition,
in contrast to normal alveolar macrophages, BAL cells from
bleomycin-challenged animals secreted significantly elevated
amounts of MIP-1a protein in response to stimulation with TNF,
but not IL-6 or bleomycin (Fig. 6B). These data suggest that
TNF can directly stimulate the late peak of MIP-1a expression
present in the bleomycin model.
DISCUSSION
In this study, we detected elevated TNF and IL-6 protein
expression in the BAL fluid of CBA/J mice 6 and 12 h
post-bleomycin challenge, whereas elevated MIP-1a protein
expression was not detected until 24 h (Fig. 1, A–C). In
addition, IL-6 and TNF protein were elevated 8, 12, and 16
days post-challenge, preceding the late peak of MIP-1a
expression 12–16 days post-challenge (Fig. 2, A and B) [8].
These data suggest that TNF and IL-6 may stimulate MIP-1a
expression in vivo. Directly supporting this contention, expres-
sion of MIP-1a mRNA was attenuated by neutralization of TNF
protein in an LPS-induced murine model of septic shock [21].
However, while primary cultures of both peritoneal and alveolar
macrophages expressed elevated levels of MIP-1a mRNA after
LPS challenge, peritoneal macrophages did not secrete ele-
vated levels of MIP-1a protein [22]. This finding suggests that
Fig. 3. Total BAL cell counts (A) and whole lung homogenate MIP-1a ELISA
analysis (B) at 2 and 10 days post-bleomycin or saline challenge in CBA/J mice
passively immunized with sTNFr or IgG. Data are expressed as mean 6 SEM,
n 5 5, *P , 0.05.
TABLE 1. Differential Cell Counts of Lavage Fluid From IgG-,










Lymphocytes 1.2 6 0.3 12.7 6 4.0b 34.0 6 9.0
Mononuclear phagocytes 21.6 6 1.0 80.1 6 34.3b 140 6 21.5
Granulocytes 2.1 6 0.7 27.1 6 12.3 59.1 6 25.4
a CBA/J mice were challenged intratracheally with saline or bleomycin,
followed by intraperitoneal injection of sTNFr or IgG 6 and 8 days post-
challenge; n 5 5 (b P , 0.05).
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investigation of MIP-1a mRNA expression is alone insufficient
to evaluate a putative stimuli for MIP-1a protein expression.
Preliminary results in a model of airway hyperreactivity have
demonstrated that neutralization of TNF may abrogate MIP-1a
protein expression in vivo [23]. Consequently, we treated
bleomycin-challenged CBA/J mice with sTNFr or anti-TNF
antibodies and measured MIP-1a protein expression by ELISA.
Consistent with the results in the septic shock and airway
hyperreactivity models, we observed decreases in the early and
late peaks of MIP-1a protein expression of 80 and 35%,
respectively. These findings unequivocally demonstrate that
TNF is a requisite for stimulation of MIP-1a protein in vivo.
In similar experiments, neutralization of IL-6 resulted in a
significant decrease in MIP-1a expression at 2 days, but not 10
days, post-bleomycin challenge. This result suggests that IL-6
may mediate MIP-1a expression during the acute inflammatory
response in the first 2 days after bleomycin challenge, but have
a lesser role during the maturation of the inflammatory lesion.
Neutralization of both IL-6 and TNF decreased MIP-1a protein
levels more than anti-IL-6 therapy alone, consistent with our
expectation that stimulation of MIP-1a protein expression is
multifactorial.
Previously, we demonstrated that MIP-1a mediates macro-
phage, but not lymphocyte, accumulation in the lungs of
bleomycin-challenged CBA/J mice [8]. It is interesting to note
that neutralization of TNF attenuated both macrophages and
lymphocyte accumulation, suggesting that TNF is more proxi-
mal than MIP-1a in a cytokine network where an additional
unidentified mediator(s) is responsible for lymphocyte recruit-
ment (Table 1). Candidates for lymphocyte recruitment include
other members of the C-C chemokine family, such as MCP-1,
MCP-2, MCP-3, RANTES, eotaxin, C10, and MIP-1b [24–26].
Many of these chemokines are chemotactic for subsets of
lymphocytes in vitro. Because our TNF and MIP-1a neutraliza-
tion experiments have only analyzed total lymphocyte popula-
tions, we may be overlooking significant changes in subsets of
lymphocytes. Nevertheless, it is reasonable to postulate that
Fig. 4. Whole lung homogenate MIP-1a ELISA analysis at 2 days post-
bleomycin or saline challenge in CBA/J mice passively immunized with IgG,
anti-IL-6 antibodies, or anti-IL-6 antibodies plus sTNFr. Data are expressed as
mean 6 SEM, n 5 5, *P , 0.05.
Fig. 5. Serial lung sections from bleomycin- (A–F) or
saline- (not shown) challenged CBA/J mice analyzed
by in situ hybridization for MIP-1a mRNA. Sections
were probed with anti-sense (A, B, E, F) or sense
probe (C, D) and/or pretreated with RNAase (inset, E,
F). Sections were counterstained with hematoxylin
and photographed at 3400 magnification. Arrows
indicate positive cells and the corresponding area on
the serial section.
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TNF is stimulating expression of chemokines other than
MIP-1a, which are mediating lymphocyte recruitment to the
lungs of bleomycin-challenged mice.
Although the above data provide significant insights into the
pulmonary cytokine responses to bleomycin challenge, they do
not provide definitive evidence for which mediators directly
stimulate MIP-1a expression. TNF has previously been shown
to be a weak, if not equivocal, stimulus for MIP-1a protein
expression from normal alveolar macrophages in vitro [27–29].
Consistent with this data, we found that normal alveolar
macrophages treated with TNF alone did not secrete signifi-
cantly elevated levels of MIP-1a protein (Fig. 6A). However,
normal alveolar macrophages did secrete significantly elevated
levels of MIP-1a protein when treated with TNF plus IL-6,
consistent with our observation that neutralization of IL-6
and/or TNF in vivo attenuates MIP-1a expression (Fig. 6A). It is
interesting that IL-6 has been described as a co-stimulus in
other systems. For example, IL-6 plus IL-10 modulated immu-
noglobulin secretion from B cells, whereas IL-6 alone did not
have a similar effect [15]. Treating alveolar macrophage
cultures with TNF, which stimulates IL-6 expression from these
cells, could theoretically stimulate MIP-1a expression. One
reason this theoretical effect was not observed may be that IL-6
and TNF need to be encountered simultaneously by the alveolar
macrophage. Once the macrophage encounters TNF in the
absence of IL-6, it may no longer be responsive to costimulation
by IL-6. Similar to TNF plus IL-6, bleomycin plus IL-6
stimulated significantly increased MIP-1a protein expression
from normal alveolar macrophages, compared to controls,
whereas bleomycin or IL-6 alone had no effect (Fig. 6A). The
rapid, bleomycin-dependent stimulation of TNF from alveolar
macrophages along with exogenously added IL-6 may be
synergizing to stimulate MIP-1a protein expression in vitro.
Alternatively, bleomycin may be directly synergizing with IL-6
to stimulate MIP-1a expression. Regardless of the mechanism,
these results provide insight into the components of the
cytokine network present in the alveolar compartment after
administration of bleomycin in vivo. During the first 12 h after
bleomycin instillation, epithelial cells, alveolar macrophages,
and endothelial cells are the likely sources of the profoundly
elevated IL-6 levels, whereas alveolar macrophages are the
predominant source of TNF (Figs. 1B and 2A) [12, 13, 30–32].
Next, at 12–24 h post-challenge, TNF and IL-6 probably
synergize to stimulate MIP-1a protein secretion from alveolar
macrophages. This putative cytokine network is consistent with
the kinetics of TNF, IL-6, and MIP-1a protein expression, and
strongly supported by the findings of decreased MIP-1a protein
levels after neutralization of TNF and IL-6 in vivo [8].
In contrast to the effects attributable to IL-6 in normal
alveolar macrophages, treatment with IL-6 plus TNF or bleomy-
cin did not significantly affect MIP-1a expression in lavage
cells isolated from animals challenged 8 days previously with
bleomycin. Addition of bleomycin to this already maximally
stimulated cell population probably had a toxic effect, whereas
addition of exogenous IL-6 was probably insignificant given the
levels of IL-6 detected in vivo at this time point. TNF alone was
the only treatment that stimulated a modest but significant
increase in MIP-1a production from the 8-day lavage cell
cultures. Supporting the finding of the modest effect of TNF on
these cultures, fibroblasts grown out of arthritic lesions and
alveolar macrophages isolated from mice previously challenged
with mineral dust also secreted only very modest amounts of
MIP-1a in response to stimulation with TNF [27, 28]. The cells
isolated from these inflammatory lesions were already signifi-
cantly activated, possibly accounting for the modest increases
in MIP-1a protein expression observed in response to addi-
tional stimuli. Supporting this contention, levels of MIP-1a
secreted from the untreated control group of lavage cells
isolated from bleomycin-challenged animals were 10 times
higher than MIP-1a levels secreted from the control group of
normal alveolar macrophages isolated from animals not chal-
lenged with bleomycin. Although these results suggest the
lavage cells isolated 8 days after bleomycin challenge are a
poor target for the evaluation of potential stimuli of MIP-1a
expression in vitro, the modest effects attributable to TNF
support the hypothesis that it is one of the stimuli for MIP-1a
protein expression late (8–16 days) during the response to
bleomycin challenge.
Fig. 6. MIP-1a ELISA analysis of normal
alveolar macrophage (A) or 8-day post-
bleomycin challenge lavage cell (B) culture
supernatants. Cells were treated for 24 h
with 5 ng/mL TNF, 5 ng/mL IL-6, and/or 5
mU bleomycin. Data expressed as mean 6
SEM, n 5 3–5, *P , 0.05.
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Another likely stimulus for MIP-1a expression is IL-1.
Previous work has established that IL-1 is a potent in vitro
stimulus for MIP-1a. Cultures of peripheral blood monocytes,
alveolar macrophages, and inflammatory fibroblasts all se-
creted significantly elevated levels of MIP-1a protein after
stimulation with IL-1 [22, 33]. Although administration of IL-1
receptor antagonist protein to bleomycin-challenged mice puta-
tively attenuated fibrosis, no link between IL-1 and expression
of specific chemoattractants, like MIP-1a, has been demon-
strated in the bleomycin model [34].
The data presented in this study support the hypothesis that
cytokine networks are activated in the lungs after bleomycin
challenge. We propose the following cytokine networks. (1) The
acute lesion: bleomycin instillation stimulates TNF, IL-6, and
possibly IL-1 secretion from airway epithelial cells and resident
alveolar macrophages. Next, TNF and IL-6 synergize to stimu-
late MIP-1a expression from alveolar macrophages, contribut-
ing to the expansion of the lesion via recruitment of mono-
nuclear phagocytes (Fig. 7, A and C), (2) The chronic lesion:
stimulated alveolar macrophages are likely secreting TNF and
IL-1, stimulating expression of MIP-1a and other chemokines
such as MCP-1, which in turn recruit additional macrophages
and lymphocytes to the expanding inflammatory lesion (Fig. 7,
B and D). The inflammatory cells recruited and modulated by
these cytokine networks are a component of the profibrotic
inflammatory nidus responsible for dysregulated collagen syn-
thesis and deposition. Similar to IPF, these processes result in
significant pulmonary pathophysiology. Although the precise
mechanism of stimulation of the profibrotic lesion is unclear, we
have identified important components of this process, providing
insights for future investigations and interventions.
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